Patent ID: 9567592
Date: 2017-02-14
CPC Classifications: A61K,A61P,C12N

Claim:
1. A method for treating a viral disease in a patient suffering from said disease, comprising infecting a target cell with a therapeutically effective amount of a recombinant retrovirus, wherein the recombinant retrovirus comprises: a 5′ long terminal repeat (LTR) comprising lentiviral R and U5 sequences and a self-inactivating lentiviral 3′ LTR; a first promoter; a first siRNA coding region located between the 5′ LTR and the 3′ LTR; and a first termination sequence; wherein the first siRNA coding region comprises a sequence that is at least about 90% identical to a target region of a pathogenic virus genome or genome transcript, or an endogenous target cell gene encoding a product that is involved in the lifecycle of an infecting pathogenic virus, wherein the target region of a pathogenic virus genome or genome transcript is a region in HIV LTR, HIV vif gene, HIV nef gene, HIV rev gene, HIV gag gene, HIV pol gene, or a transcript thereof, and wherein the product encoded by the endogenous target cell gene is CD4, CXC chemokine receptor 4 (CXCR4), CC chemokine receptor 5 (CCR5), cyclophilin, CRM-1, importin-β, HP68, or a cellular receptor that are involved in recognition by adenoviruses, cytomegalovirus, coxsackieviruses, hepatitis A virus, hepatitis C virus, HIV, HSV, influenza virus, measles virus, poliovirus, human papillomavirus, or a combination thereof.